Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.17/2983
Título: Antiphospholipid Syndrome and Recurrent Thrombosis--Limitations of Current Treatment Strategies
Autor: Coelho Henriques, C
Lourenço, F
Lopéz, B
Panarra, A
Riso, N
Palavras-chave: Antibodies, Antiphospholipid
Antiphospholipid Syndrome
Bronchoscopy
Diagnosis, Differential
Humans
Male
Middle Aged
Pulmonary Embolism
Risk Factors
Thrombosis
Tomography, X-Ray Computed
HCC MED
Data: 8-Mar-2012
Editora: BMJ Publishing Group
Citação: BMJ Case Rep. 2012 Mar 8;2012. pii: bcr1120115147
Resumo: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder that is characterised by the presence of antiphospholipid antibodies and a common cause of vascular thromboembolic phenomena. The management of patients with APS is currently directed to antithrombotic medications. The international therapeutic guidelines recommend oral anticoagulation with warfarin indefinitely after the first thrombotic episode. However, therapeutic guidelines lack for a minority group of patients - the patients appropriately anticoagulated with recurrent thromboembolic phenomena. The authors present a clinical report that reveals the therapeutic and diagnostic complexity of this specific group of patients. Regarding recent studies, APS has been revealed as a complex syndrome with multiple pathophysiological mechanisms previously unknown. In this context, new therapeutic approaches have been defended and empirically experienced, with potentially promising results.
Peer review: yes
URI: http://hdl.handle.net/10400.17/2983
DOI: 10.1136/bcr.11.2011.5147
Aparece nas colecções:MED - Artigos

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
BMJ Case Rep 2012.pdf1,69 MBAdobe PDFVer/Abrir


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.